Who is sponsoring NCT01402193?

NCT01402193 is sponsored by Fudan University.

What condition does NCT01402193 study?

NCT01402193 studies Breast Cancer.

What drugs are being tested in NCT01402193?

Interventions: Pre-radiotherapy commencement of Arimidex, Post radiotherapy commencement of Arimidex, Radiotherapy, Radiotherapy.

What is the status of NCT01402193?

NCT01402193 is currently UNKNOWN.

Last reviewed 2014-06-24 · How we verify

A Prospective, Randomized, Bi-center Study to Compare the Outcome of Adjuvant Radiotherapy With Concomitant or Sequential Arimidex in Postmenopausal Women With Breast Cancer

NCT01402193 Phase 3 UNKNOWN

The purpose of this study is to compare TGF-β1 change in concomitant with that in sequential Arimidex in postmenopausal women with breast cancer, as measured by the proportion of patients with an elevation of TGF-β1 level at the 4th week after initiation of radiotherapy relative to the pre-treatment baseline.

Details

Lead sponsor	Fudan University
Phase	Phase 3
Status	UNKNOWN
Enrolment	220
Start date	2011-07
Completion	2015-07

Conditions

Breast Cancer

Interventions

Pre-radiotherapy commencement of Arimidex
Post radiotherapy commencement of Arimidex
Radiotherapy
Radiotherapy

Primary outcomes

Level of TGF-β1 — First analysis will occur 1 year after first subject enrolled
To compare TGF-β1 change in concomitant with that in sequential Arimidex in postmenopausal women with breast cancer, as measured by the proportion of patients with an elevation of TGF-β1 level at the 4th week after initiation of radiotherapy relative to the pre-treatment baseline.

Countries

China